Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Initiation and intensification of antihyperglycemic therapy in type 2 diabetes mellitus: Update of Russian Association of Endocrinologists expert consensus document (2015)

Cover Page

Abstract


The current update of the consensus algorithm of initiation and intensification of the antihyperglicemic therapy in treatment of the patients with type 2 diabetes mellitus (2015) is based on the preliminary document issued by the Russian Association of the Endocrinologists in 2011.
The update was needed due to new data on the safety of the traditional therapeutic options, availability of the new class of the antidiabetic medications, and necessity to add chapter about initiation and intensification of the insulin therapy.
The patient-centered approach remains the absolute priority at any stage of diabetes care as it ensures the efficacy and safety of antihyperglycaemic treatment.

Ivan Ivanovich Dedov

Endocrinology Research Centre, Moscow

Email: post@endocrincentr.ru

Russian Federation MD, PhD, Professor, Academician of Russian Academy of Sciences, Director of Endocrinology Research Centre

Marina Vladimirovna Shestakova

Endocrinology Research Centre, Moscow; I.M.Sechenov First Moscow State Medical University, Moscow

Email: nephro@endocrincentr.ru

Russian Federation MD, PhD, Professor, corresponding member of Russian Academy of Sciences, Head of the Diabetes Institute of Endocrinology research centre, Chief of the Pediatric endocrinology and diabetology chair of Sechenov University

Alexander Sergeevich Ametov

Russian Medical Academy of Postgraduate Education, Moscow

Email: alexander.ametov@gmail.com

Russian Federation MD, PhD, Professor, Head of the endocrinology department

Mikhail Borisovich Antsiferov

Moscow Department of Health, Moscow

Email: antsiferov@rambler.ru

Russian Federation ME, PhD, Professor, Cheif endocrinologist of Moscow-City

Gagik Radikovich Galstyan

Endocrinology Research Centre, Moscow; I.M.Sechenov First Moscow State Medical University, Moscow

Email: mariagrishina2006@yandex.ru

Russian Federation MD, PhD, Professor, Head of the Diabetic foot department of Endocrinology research centre

Alexander Yur'evich Mayorov

Endocrinology Research Centre, Moscow; I.M.Sechenov First Moscow State Medical University, Moscow

Email: education@endocrincentr.ru

Russian Federation MD, PhD, Head of the Programme education and therapy department of Endocrinology research centre

Ashot Musaelovich Mkrtumyan

State University of Medicine and Dentistry named after A.I.Evdokimov, Moscow

Email: vagrashot@mail.ru

Russian Federation MD, PhD, Professor, Chief of the Endocrinology Chair

Nina Alexandrovna Petunina

I.M.Sechenov First Moscow State Medical University, Moscow

Email: NAPetunina@mail.ru

Russian Federation MD, PhD, Professor, Head of the Endocrinology department of postgraduate faculty

Olga Yur'evna Sukhareva

Endocrinology Research Centre, Moscow

Author for correspondence.
Email: olgasukhareva@mail.ru

Russian Federation MD, PhD, Cheif researcher of the Diabetes nephropathy department of Endocrinology research centre

  1. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). // Сахарный диабет. – 2015. – Т.18. – №1S. – С. 1–112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1–112.] doi: 10.14341/DM20151S1-112.
  2. Дедов И.И., Шестакова М.В., Аметов А.С., и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. // Сахарный диабет. – 2011. – №4. – С. 6–17. [Dedov II, Shestakova MV, Ametov AS, et al. Russian Association of Endocrinologists expert consensus document on initiation and intensification of antyhyperglycaemic therapy in type 2 diabetes mellitus. Diabetes mellitus. 2011;14(4):6–17.] doi: 10.14341/2072-0351-5810.
  3. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine practice. 2009;15(6):540–559. doi: 10.4158/EP.15.6.540.
  4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429–442. doi: 10.1007/s00125-014-3460-0.
  5. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England journal of medicine. 2008;358(24):2545–2559. doi: 10.1056/NEJMoa0802743.
  6. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. The New England journal of medicine. 2009;360(2):129–139. doi: 10.1056/NEJMoa0808431.
  7. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.
  8. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine. 2008;358(24):2560–2572. doi: 10.1056/NEJMoa0802987.
  9. Дедов И.И., Шестакова М.В., Александров А.А., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (6-й выпуск). // Сахарный диабет. – 2013. – №1(приложение 1). – С. 1–120. [Dedov II, Shestakova MV, Aleksandrov AA, Galstyan GR, Grigoryan OR, Esayan RM, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). Diabetes mellitus. 2013;16(1S):1–120.] doi: 10.14341/DM20131S1-121.
  10. Lipska KJ, Bailey CJ, Inzucchi SE. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes care. 2011;34(6):1431–1437. doi: 10.2337/dc10-2361.
  11. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52(3):741–750.
  12. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55(6):1695–1704. doi: 10.2337/db05-1602.
  13. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684.
  14. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England journal of medicine. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889.
  15. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocrine reviews. 2012;33(2):187–215. doi: 10.1210/er.2011-1052.
  16. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessent. The New England journal of medicine. 2014;370(9):794–797. doi: 10.1056/NEJMp1314078.
  17. Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. British journal of pharmacology. 2003;140(1):123–132. doi: 10.1038/sj.bjp.0705397.
  18. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270–2276. doi: 10.2337/diabetes.48.12.2270.
  19. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes care. 2007;30(2):389–394. doi: 10.2337/dc06-1789.
  20. U.S. Food and Drug Administration. FDA News Release (25-nov-2013): FDA requires removal of certain restrictions on the diabetes drug Avandia. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm
  21. Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58(3):493–504. doi: 10.1007/s00125-014-3456-9.
  22. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug design, development and therapy. 2014;8:1335–1380. doi: 10.2147/DDDT.S50773.
  23. American Diabetes Asosiation. Approaches to Glycemic Treatment. Diabetes care. 2015;38(Supplement 1):S41–S48. doi: 10.2337/dc15-S010.
  24. Rosenstock J, Jelaska A, Frappin G, et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes care. 2014;37(7):1815–1823. doi: 10.2337/dc13-3055.
  25. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathwys and review of ongoing outcome trials. Diabetes & vascular disease research. 2015;12(2):90–100. doi: 10.1177/1479164114559852.
  26. Дедов И.И., Шестакова М.В., Абусуев С.А., и др. Оптимизация и интенсификация инсулинотерапии при сахарном диабете 2 типа (клинические рекомендации). // Сахарный диабет. – 2010. – №5. – С. 9–16. [Dedov II, Shestakova MV, Abusuev SA, Valeeva FV, Verbovoy AF, Galstyan GR, et al. Optimizatsiya i intensifikatsiya insulinoterapii pri sakharnom diabete 2 tipa (klinicheskie rekomendatsii). Diabetes mellitus. 2010;13(5):9–16.] doi: 10.14341/2072-0351-6049.

Supplementary files

There are no supplementary files to display.

Views

Abstract - 2708

PDF (Russian) - 3574

Cited-By


PlumX


Copyright (c) 2015 Dedov I.I., Shestakova M.V., Ametov A.S., Antsiferov M.B., Galstyan G.R., Mayorov A.Y., Mkrtumyan A.M., Petunina N.A., Sukhareva O.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.